Study of the Disease Process of Lymphangioleiomyomatosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-100
SponsorNational Heart, Lung, and Blood Institute (NHLBI)
About this trial
Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor.
This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy.
Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Toshibia Aquilion One CT
Treatment groups
2,000 Participants
are divided into 1 treatment groupLocations
1National Institutes of Health Clinical Center20892, BethesdaMaryland, United States
Sponsors and collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Lead sponsor
Source ClinicalTrials.gov